CMPS vs. ABUS, LRMR, VERV, ALT, KALV, TVTX, OCS, STTK, ATXS, and APLT
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Arbutus Biopharma (ABUS), Larimar Therapeutics (LRMR), Verve Therapeutics (VERV), Altimmune (ALT), KalVista Pharmaceuticals (KALV), Travere Therapeutics (TVTX), Oculis (OCS), Shattuck Labs (STTK), Astria Therapeutics (ATXS), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical preparations" industry.
Arbutus Biopharma (NASDAQ:ABUS) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Arbutus Biopharma received 375 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 76.92% of users gave COMPASS Pathways an outperform vote while only 70.83% of users gave Arbutus Biopharma an outperform vote.
Arbutus Biopharma has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500.
In the previous week, COMPASS Pathways had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for COMPASS Pathways and 6 mentions for Arbutus Biopharma. COMPASS Pathways' average media sentiment score of 1.05 beat Arbutus Biopharma's score of 0.26 indicating that Arbutus Biopharma is being referred to more favorably in the media.
Arbutus Biopharma has higher revenue and earnings than COMPASS Pathways. Arbutus Biopharma is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma currently has a consensus target price of $4.33, suggesting a potential upside of 54.21%. COMPASS Pathways has a consensus target price of $47.40, suggesting a potential upside of 472.46%. Given Arbutus Biopharma's higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Arbutus Biopharma.
COMPASS Pathways has a net margin of 0.00% compared to COMPASS Pathways' net margin of -572.81%. Arbutus Biopharma's return on equity of -57.24% beat COMPASS Pathways' return on equity.
43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 4.0% of Arbutus Biopharma shares are owned by insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
COMPASS Pathways beats Arbutus Biopharma on 10 of the 16 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
